Tadalafil (TDL) has poor bioavailability due to the less aqueous solubility and bitter taste. Oral solid dosage forms, especially tablets, have a broad market worldwide. Constraints of tablets are a long process, pollution, high processing cost, and requiring more excipient. The research was performed to optimize an eco-friendly immediate-acting pastille of TDL to put forward an alternate formulation to a tablet using advanced data mining tools. Another objective is to assess the taste masking of TDL using the Brief Access Taste Aversion (BATA) model. The amount of PEG-4000, Polyox N-10, and Kyron T-314 were chosen as critical material attributes from failure mode effect analysis. Box-Behnken design (BBD) was utilized to optimize the pastilles and ascertained the significant impact of chosen variables on disintegration time and % CDR at 10 min. The control strategy and optimal region were located using an overlay plot. The pastilles were able to release the drug within 15 min due to faster disintegration. The formulated pastilles were of uniform size, shape, and mechanical strength. The bitter taste of TDL was masked and confirmed by the BATA model. The newer formulation may be helpful in the industry due to its eco-friendly, single-step, and economical process. It unlocks a new direction in the field of oral solid dosage form as an alternative to tablets.
Background: The intersubject variability which was related to the genetic makeup was the major cause of change in pharmacological and pharmacokinetic behavior of same dosage form in varied human being. 3D printing technology will help therapy evolve and eliminate the limitations of conventional technologies. Nebivolol's (NBL)-limited oral bioavailability is mainly due to its poor aqueous solubility. The research aims to combine advanced 3D printing technology and nanotechnology to design customized therapy and enhance the functionality of NBL using a statistical approach. Results and discussion: The results of the phase solubility indicated that NBL was a poorly aqueous soluble drug. Its solubility was increased by employing nanoparticle drug delivery, which is a promising solubility enhancement technique. The 32 full factorial design was employed to develop and optimize bionanoparticles (BNPs) by solvent evaporation technique using poly (lactic-co-glycolic acid 50:50) (PLGA 50:50) and poloxamer-407 as a surfactant. The BNPs were characterized by % encapsulation efficiency (% EE), Fourier transform infrared spectroscopy (FTIR) and differential scanning calorimeter (DSC), transmission electron microscope (TEM), zeta potential, polydispersity index (PDI), particle size, in vitro drug release, etc. The BNPs loaded of NBL were further incorporated into the multichannel 3D-controlled release tablets made by PVA filaments employing fused deposition modeling (FDM) technology optimized by central composite design (CCD). Multichannel 3D-printed bionanoparticles-loaded tablet (M3DPBT) was optimized using CCD. All designed M3DPBTs were evaluated for post-fabrication parameters. The optimized M3DPBT could release more than 85% NBL within 10 h. Conclusions: The newly fabricated M3DPBT was found stable. The amount of PLGA 50:50 and Polaxomer was significant for developing BNPs. % infill and layer height were observed as critical for the designing M3DPBT. The combined novel 3D printing and nanotechnology technology will open a new direction for patient compliance and better therapeutic effects. Graphical Designing and developing of M3DPBT is substantially improve the patient compliance and therapeutic effectiveness of Nebivolol.
Background: A combination of Glimepiride and Boswellia serrata extract reduces neuropathic diabetic complications by reducing the peroxidase level and improving the antioxidant level. The hybrid liquisolid method includes a combination of two methods, kneading and the liquisolid method, to enhance the drug’s in-vitro performance. Objective: The objective of this study was to enhance the in-vitro performance of antidiabetics drugs. Method: Tablets involving a fixed-dose combination of Glimepiride and Boswellia serrata extract were formulated by kneading method followed by liquisolid method. Screening of non-volatile solvents, carriers, and coating materials was carried out. The experiment was designed to optimize the formulation and the obtained model was validated concerning the design of the experiment. 3 level 2 factorial (32) design was applied by using Design expert software 11. Various pre-compression parameters were assessed to check the quality of the formulation. Results: Screening of excipients for kneading method, including Glimepiride with PVP K 30 (5%), and Boswellia serrata extract with Poloxamer 188 (13%), provided optimum drug release. For the liquisolid method, propylene glycol:PEG 400: Tween 80 (1:2:4) ratio for Glimepiride and PEG 400: Tween 80 (1:3) ratio for Boswellia serrata extract were selected. Common carrier and coating material for both drugs were selected to improve the in-vitro performance of the drug. Conclusion: This study enables an overall understanding of the impact of excipients on the quality of formulation, which may provide critical knowledge for the implementation of liquisolid systems.
Background Biliary excretion and poor aqueous solubility are significant concerns about Rosuvastatin's (RSV) low oral bioavailability. Incorporating the green chemistry concept into the formulation at an industrial scale is another major concern nowadays. Objective The present study aimed to develop immediate-release (IR) pastilles of RSV and Piperine (PIP) using advanced data mining tools and exploring the concept of green chemistry. The secondary objective was to develop and validate the analytical method for estimating RSV and PIP. Methods The Q-absorbance ratio method was developed and validated to estimate both drugs in formulation. The IR pastilles were formulated using a modified method incorporating a laboratory-scale pastillator. The pastilles were formulated by mixing, melting and solidifying the mixture in a single-step process. The concept of green chemistry, i.e., no use of organic solvent and no dust generation, was accomplished. The PIP was used as a bioenhancer, preventing RSV from entering the bile and increasing bioavailability and systemic exposure in the body. The RSV and PIP solubility were improved by formulating the pastilles using the hydrophilic carrier. The Box Behnken design (BBD) was applied to optimize pastilles. The amount of Soluplus, Primellose, and PEG 6000: HPMC E5 ratio were taken as critical material attributes (CMAs), and disintegration time, % CDR of RSV, and PIP were taken as critical quality attributes (CQAs). Various physical and drug-related evaluation parameters characterized the pastilles. Results The developed Q absorbance method for estimating RSV and PIP was accurate, precise, and robust. The observed isobestic point was 283 nm. QbD was implemented to develop a quality product and to find design space. BBD revealed a significant relationship between the chosen CQAs and CMAs. The optimal pastilles were composed of 42.33 mg Soluplus, 5.9% Primellose, 63.84 mg PEG-6000 and 27.36 mg HPMC E5. The designed pastilles were of uniform size and shape and had the desired characteristics. The formulation released a drug > 85% in an hour using Soluplus as a solubility enhancer and Primellose as a super disintegrant. Conclusion The unexplored formulation, pastilles of RSV and PIP, was successfully developed in a single step, which has a faster dissolution rate, accomplishing a systematic approach. Green chemistry was explored using no organic solvent with no dust generation, leading to less pollution. The newer approach of formulating pastilles might apply to the industry as it is environment-friendly, single-step, and uses fewer excipients. Graphical Abstract